After Hours Summary: OCX +48% on encouraging lung cancer diagnostic blood test results, XLRN +11% on Luspatercept phase III dataAfter Hours Gainers:
Companies trading higher in after hours in reaction to news: OCX +47.5% (reports 'encouraging' new study results for lung cancer blood test), XLRN +10.8% / CELG +0.7% (Celgene and Acceleron announce Luspatercept achieved primary and all key secondary endpoints in Phase III BELIEVE study), ARA +3.1% (light volume; American Renal Associates and UnitedHealthcare reach settlement), SFUN +2.4% (Fang signs non-binding memorandum to acquire 10% equity interest in Chongquing Wanli New Energy for RMB200 mln), DNLI +2.1% (still checking), HEAR +2% (initiated with a Buy at DA Davidson), PCAR +1.1% (announces $300 mln share repurchase of common stock), SFIX +0.7% / WTW +0.6% (initiated with Overweight ratings at KeyBanc Capital Mkts), CBOE +0.3% (initiated with a Buy at Compass Point; tgt $115)
After Hours Losers:
Companies trading lower in after hours in reaction to news: ADMP -6.4% (files for $150 mln mixed securities shelf offering), WHD -5.3% (commences 10 mln share Class A common stock offering; provides prelim Q2 expectations with revs of $136.0-139.0 mln vs. $126.60 mln Capital IQ Consensus Estimate) DAC -4% (files for 99,342,271 share common stock offering by selling shareholders), LOXO -1.6% (attributed to block trade pricing), JWN -1% / URBN -0.7% (downgraded to Sector Weight at KeyBanc Capital Mkts),
![]()